

## Perfect Screening Test

- Always correct
- Repeatable
- Safe, painless, quick, inexpensive
- Makes a clinical difference

Reality is Quite a Different Prospect!

Basic Two by Two							
Test	Gold Sta Disease Positive						
Positive	True Positives	False Positives					
Negative	False Negatives	True Negatives	5				
		in	2				

## Sensitivity

- Proportion of those with disease defined by gold standard testing who are labeled by the test in question as positive
- True positives/ all subjects with gold standard proven disease

## Specificity

- Proportion of those without disease defined by gold standard testing who are labeled as negative by the test in question
- True Negatives/ all subjects disease free by gold standard testing


## Prevalence

- In the 2x2 table: the number of those with disease by gold standard ie 5/100,000
- Clinically Pretest Probability of the patient is very similar (ie 30% chance of a disease based on risk factors)

## Defining a Positive Test


- Tests are usually yield a continuous variable
- An artificial cut off is needed to define the positive or abnormal values from the normal or negative values.
- The Receiver operating characteristic curve demonstrates the trade off


## ROC Curve




- As specificity is increased sensitivity is lost.
- The closer to the upper left corner your values yield the better balance in the test characteristics.

#### Example Disease: " an uncontrollable urge to watch a football team without any hope of winning (especially bowl games)" We know from research at LUMC that in our medical school this disease occurs in 1 in 10 medical students Jeff's Test is questionnaire available and has defined sensitivities and specificities by population testing n 2000 medical students Have ND Don't Have ND Jeff's Test False Positives True Positives Positive False Negatives True Negatives Negative 200 with ND 1800 without ND







## Predictive Value


#### **Positive Predictive Value**


- The proportion of patients testing positive who actually have the disease (by gold standard)
- True Positives / All positives


## **Predictive Value**


#### **Negative Predictive Value**

- The Proportion of patients testing negative who are truly free of the disease (by gold standard)
- True Negatives / All Negatives











## The point is . . .

- Sensitivity and Specificity are functions of the operating curves of the test
- Predictive Values are related to prevalence or pre test probabilities
- Statistical difference doesn't necessarily relate to clinical relevance
- Clinically Rule In/ Rule Out may not be accomplished by one test






## Which test is better?


Likelihood ratios compare probabilities of true results to false results


- Likelihood ratio of a positive test is probability of a true positive (given disease) to false positives (without disease)
- Likelihood ratio of a negative test is probability of a false negative (with disease) to a true negative (without disease)




# And . . . Likelihood ratio of a negative test is $\frac{100\% - Sensitivity}{Specificity}$ The smaller the likelihood ratio of a negative test the better the ability to rule out disease







- What are the results to my patient
   The costs of false positives or false negatives
  - Morbidity, Cost and Consequences



# Now that you have the tools....

- Should you screen for the disease ?
- In whom to screen ?
- How to do the screening ?
- When should screening start and how often?

## Should you screen?

- Screening should be done if a particular disease will go on to cause substantial morbidity or mortality (what's the harm in a little football...)
- Screening is of little utility if the natural history of the disease cannot be changed or treatment of asymptomatic cases is not different from symptomatic ones.


## What can go wrong?

- Diagnostic Test Errors
  - Biologic Variability
     Measurement error
     random
    - systematic
  - Intra observer variability
  - Inter observer variability

#### Lead time bias A problem found when determining if screening and subsequent treatment changes the natural history <u>Asymptomatic</u> <u>Symptoms</u> <u>Asymptomatic</u> <u>A</u>

## Length bias

- Causes one to conclude that screening does not change outcomes
- In disease with a heterogeneous population, slowly progressive states will be caught more frequently by screening (prior to symptoms) and skews the data towards less benefit. Randomization usually eliminates this by sampling equal numbers of each disease subset



## **Self Selection Bias**

If you create the screening protocol two patient populations appear

- Those who make sure they are screened repeatedly ( diminishing returns)
- Those who are rarely seen and probably most need it (i.e. TB screening yields higher benefit in homeless persons but they rarely seek medical care --- access issues)

	Who do you screen? If the disease incidence or prevalence is low what is the utility of screening							
	Given a Test with a sensitivity of 80% and a specificity of 90%: Pretest Probability 1% 10% 50% 90%							
	Positive Predictive Value	7.5%	47.1%	88.9%	98.6%			
	Negative Predictive Value	99.8%	97.6%	81.8%	33.3%			

## How do you overcome this?

By serial or consecutive testing


#### Positive if Both

Both tests verify the same population HIV testing with Elisa and Western Blot

#### Positive if One

Two tests to detect different types of disease
 Flexible Sigmoidoscopy and FOBT testing

# Which test to use first? Now back to the Likelihood ratios if false positives and negative are equal If not then.... Time to be a clinician



Morbidity and Mortality

Effective Treatment given early stage

## Who gets the disease?

- Screening men for ovarian cancer?
- Screening children for prostate cancer?

More seriously.....

Cholesterol in adults, Pap smears and Mammograms in adult women, colon cancer screening at 50

### Does it matter?

 Does the disease cause significant morbidity and mortality
 In economic terms is it cost effective to

screen if the incidence of disease is so rare (newborn screenings for thyroid, PKU or ultrasound for ovarian cancer) or

 Cost prohibitive to perform (AAA ultrasound screening) in a low prevalence

## Can I make a difference?

Early detection doesn't matter if treatment

- Isn't effective
- Not available
- Has a high morbidity or mortality
- Isn't readily available

## So are you totally confused??

#### Basically:

- Inherent properties of the test: precision, accuracy, clinical reproducibility
- Biologic variation: is the population operating curve well defined with little overlap between healthy and sick
- Is the Gold Standard truly gold?
- Test Characteristics: sensitivity, specificity and the difference to PPV,NPV
- Is the Likelihood ratio high for Rule In or low for Rule out, and has the weight of false positives and negatives been examined

## Think like a doctor??

#### Again

- Is there substantial morbidity if not treated
  Does finding it make a clinical difference
  Could length or lead bias explain the difference (read about Prostate and Breast Cancer now)
- Can you improve outcomes with duel testing strategies

